News

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...
The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.
The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...
Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...
Moderna Inc. jumped by 8.83 percent on Tuesday to close at $32.54 apiece as investor sentiment was boosted by a lawsuit filed ...
Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when ...
Moderna’s cash flow issues are more immediate than those of its peers, so the new provision could have a greater impact on ...